Fumarase (44-510) Human Protein
Specifications
| Product Data | |
| Species | Human |
|---|---|
| Expression Host | E. coli |
| Expression cDNA Clone or AA Sequence | |
| Predicted MW | 50.2 kDa (467aa) confirmed by MALDI-TOF |
| Concentration | 1mg/ml (determined by Bradford assay) |
| Purity | > 95% by SDS-PAGE |
| Presentation State | Purified |
| Buffer | Liquid in. 20mM Tris-HCl buffer (pH 8.0) |
| Bioactivity | Specific activity is > 25 unit/mg, and is defined as the amount of enzyme that cleaves 1umole of L-Malate to Fumarate per minute at pH 7.5 at 37C. |
| Endotoxin | < 1 EU per 1ug of protein (determined by LAL method) |
| Preparation | Liquid purified protein |
| Recommended Dilution | SDS-PAGE, Enzyme Activity |
| Protein Description | Recombinant Fumarase was expressed in E.coli and was purified by conventional chromatography techniques. |
| Storage | Can be stored at +2°C to +8°C for 1 week. For long term storage, aliquot and store at -20°C to -80C. Avoid repeated freezing and thawing cycles. |
| Stability | Shelf life: one year from despatch. |
| Shipping | Blue Ice |
| Reference Data | |
| RefSeq | NP_000134 |
| Locus ID | 2271 |
| UniProt ID | P07954 |
| Cytogenetics | 1q43 |
| Synonyms | Fumarate hydratase, FH, HLRCC, LRCC, MCL, MCuL1, Fumarate hydratase Fumarase, Fumarate hydratase mitochondrial, MCuL 1, Multiple hereditary cutaneous leiomyomata. |
| Summary | The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extended form, differing only in the translation start site used. The N-terminal extended form is targeted to the mitochondrion, where the removal of the extension generates the same form as in the cytoplasm. It is similar to some thermostable class II fumarases and functions as a homotetramer. Mutations in this gene can cause fumarase deficiency and lead to progressive encephalopathy. provided by RefSeq, Jul 2008 |
| Protein Categories | Cancer: Bladder, Cancer: Endocrine, Endocrine and metabolic diseases, Intracellular Proteins |
| Protein Families | 1ug, 2ug) in assay buffer. 3. Record the increase in A260 nm for 10 minutes - L-Malate (Sigma-Aldrich. Cat. No, 3635) - plate reader (PerkinElmer, 50 mM L-malic acid). 2. Add 50 ul of recombinant Fumarase protein with various concentrations (0.5 ug, Cat. No, M-1000) - 96 well UV plate (Costar, Protocol: Activity Assay 1. Prepare 1.45 ml assay buffer (Assay buffer: 100 mM potassium phosphate, VICTORX3) |
| Protein Pathways | Citrate cycle (TCA cycle), Metabolic pathways, Pathways in cancer, Renal cell carcinoma |
Reviews
Documents
| FAQs |
| SDS |
Resources
| Recombinant Protein Resources |
Citations
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.